Search
News & Events
The Kids researchers named as finalists in 2023 Premier’s Science AwardsFive The Kids Research Institute Australia researchers working across diverse and highly impactful areas of child health research have been named as finalists for the 2023 Premier’s Science Awards.
News & Events
International Day of Education: AI and Education at The Kids Research InstituteToday, 24 January 2025, is International Day of Education, a global celebration of the power of learning to transform lives. This year’s theme, “AI and Education: Preserving Human Agency in an Automated World”, underscores the critical role of education in preparing kids for a future increasingly shaped by AI.
News & Events
Allied Health award for respiratory researcher Dr Pamela LairdCongratulations to respiratory health clinician-researcher Dr Pamela Laird, who has won Allied Health Researcher of the Year at the WA Excellence in Allied Health Awards.
News & Events
Research to see if AI can speed up therapy for people with antibiotic-resistant bacterial infectionsResearchers from the Wal-yan Respiratory Research Centre are aiming to combine artificial intelligence with natural, infection-fighting viruses to help save lives from an increasingly common medical emergency found in hospitals.
News & Events
How summer bushfires can impact your family’s healthBushfires can have a considerable impact on our health, with some symptoms lasting long after the flames are extinguished. And our children are amongst the most vulnerable.
Research
Airway macrophages display decreased expression of receptors mediating and regulating scavenging in early cystic fibrosis lung diseaseCystic fibrosis (CF) airway disease is characterized by chronic inflammation, featuring neutrophil influx to the lumen. Airway macrophages (AMs) can promote both inflammation and resolution, and are thus critical to maintaining and restoring homeostasis. CF AM functions, specifically scavenging activity and resolution of inflammation, have been shown to be impaired, yet underlying processes remain unknown.
Research
Prevalence of tracheobronchomalacia is higher than previously reported in children with cystic fibrosisTracheobronchomalacia (TBM) is estimated to be present in 1 in 2100 children. Previous reports suggest the prevalence is higher in children with cystic fibrosis (CF). This has clinical implications with potential to influence airway clearance and lung health.
Research
BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosisCystic fibrosis (CF) is a rare, inherited, life-limiting condition predominantly affecting the lungs, for which there is no cure. The disease is characterized by recurrent pulmonary exacerbations (PEx), which are thought to drive progressive lung damage. Management of these episodes is complex and generally involves multiple interventions targeting different aspects of disease. The emergence of innovative trials and use of Bayesian statistical methods has created renewed opportunities for studying heterogeneous populations in rare diseases.
Research
Learning to make a difference for chILD: Value creation through network collaboration and team scienceAddressing the recognized challenges and inequalities in providing high quality healthcare for rare diseases such as children's interstitial lung disease (chILD) requires collaboration across institutional, geographical, discipline, and system boundaries. The Children's Interstitial Lung Disease Respiratory Network of Australia and New Zealand (chILDRANZ) is an example of a clinical network that brings together multidisciplinary health professionals for collaboration, peer learning, and advocacy with the goal of improving the diagnosis and management of this group of rare and ultra-rare conditions.
Research
Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trialThere has been renewed interest in the therapeutic use of bacteriophages (phages); however, standardised therapeutic protocols are lacking, and there is a paucity of rigorous clinical trial data assessing efficacy.